A Dieulafoy's lesion is a vascular abnormality consisting of a large caliber-persistent tortuous submucosal artery. A small mucosal defect with the eruption of this protruding vessel can cause bleeding. In fact, a Dieulafoy's lesion is a relatively rare but potentially life-threatening condition. It accounts for 1% to 2% of cases of acute gastrointestinal bleeding. Although there is no consensus on the treatment of Dieulafoy's lesions; treatment options depend on the mode of presentation, site of the lesion, and available expertise. Endoscopic therapy is usually successful in achieving primary hemostasis, with hemostasis success rates reaching 75% to 100%. Although various therapeutic endoscopic methods are used to control bleeding in Dieulafoy's lesions, the best method for endoscopic intervention is not clear. Combination endoscopic therapy is known to be superior to monotherapy because of a lower rate of recurrent bleeding. In addition, mechanical therapies including hemostatic clipping and endoscopic band ligation are more effective and successful in controlling bleeding than other endoscopic methods. Advances in endoscopic techniques have reduced mortality in patients with Dieulafoy's lesionfrom 80% to 8%-and consequently, the need for surgical intervention has been reduced. Currently, surgical intervention is used for cases that fail therapeutic endoscopic or angiographic interventions.
INTRODUCTION
A Dieulafoy' s lesion in the gastrointestinal (GI) tract, initially described by the French surgeon Dieulafoy as exulceratio simplex in 1898, is a rare but important cause of GI bleeding. 1, 2 It is defined as a vascular abnormality consisting of a large-caliber, persistent, tortuous submucosal artery. The artery fails to taper as it reaches the mucosa and hence has a diameter of 1 to 5 mm, which is 10-time thicker than the normal size of an artery at that level. [3] [4] [5] [6] Microscopically, the artery protrudes through a small mucosal defect that is typically 2 to 5 mm long and does not show any other abnormality of the arterial wall. Ulceration is limited to the overlying mucosa, whereas the surrounding mucosa appears histologically normal. 5 Up to 6% of nonvariceal bleeding in the upper GI tract 7, 8 and 1% to 2% of all acute GI hemorrhage 6, 9 are caused by a Dieulafoy's lesion. SomeClin Endosc 2015; 48:112-120 times, massive bleeding from this lesion can have a fatal clinical outcome unless adequate treatment is promptly initiated 10, 11 and mortality rates (approximately 5%) are similar to those of other causes of GI bleeding. 12 
PATHOGENESIS AND ANATOMIC DISTRIBUTION
Once believed to be acquired and aneurysmal in nature, 13 pathological reports have failed to associate Dieulafoy's lesion to aneurysms, arteriosclerosis, elastic tissue abnormalities, or signs of vasculitis. 1, 6, 14, 15 In younger patients, a congenital defect may bring a large submucosal artery in close apposition with the mucosa. 9, 14, 16 To date, the exact mechanism that triggers the bleeding is not fully understood. Several mechanisms have been proposed to explain the rupture and subsequent massive hemorrhage. One mechanism focuses mainly on the combined effect of atrophy and ischemia of the mucosa. The pulsation in a thick, large submucosal artery applies pressure to the overlying epithelium and leads to a small erosion and rupture of the vessel towards the lumen. 1, 6, 17 Clinically, Dieulafoy's lesion presents with intermittent and painless GI bleeding. 4, 18 Another theory suggests that thrombosis within the artery and subsequent ne-
INVESTIGATIONS OF DIEULAFOY'S LESION Endoscopy
The endoscopic criteria that define a GI Dieulafoy's lesion are the following: 7 (1) active arterial spurting or micropulsatile streaming from a minute (<3 mm) mucosal defect or through normal surrounding mucosa; (2) visualization of a protruding vessel with or without active bleeding within a minute mucosal defect or through normal surrounding mucosa; and (3) the appearance of a fresh, densely adherent clot with a narrow point of attachment to a minute mucosal defect or mucosa of normal appearance.
A Dieulafoy's lesion is usually diagnosed using endoscopy (Fig. 1) . Diagnosis is most easily performed during or immediately following an episode of bleeding, but the endoscopic diagnosis may be difficult, especially during the first episode, because of the small nature of the lesion, normal appearance of the surrounding mucosa, and intermittent nature of the hemorrhage. Therefore, multiple endoscopies are often necessary for diagnosis. 12, 20, 26 Approximately 49% of these lesions are identified during an initial endoscopic examination; however, 33% of lesions require more than one endoscopy to correctly identify the source of the bleeding. 25 Endoscopic ultrasonography (EUS) has also been used to aid endoscopic diagnosis by revealing a tortuous submucosal vessel near the mucosal defect. 27, 28 Push enteroscopy, which is an extension of upper GI endoscopy, allows assessment and direct evaluation of the small intestine with a diagnostic yield of 70% to 100% in patients with obscure GI bleeding. 29 Successful localization of a Dieulafoy' s lesion has also been achieved using wireless capsule endoscopy, which has the benefit of being minimally invasive; however, it does not allow therapeutic intervention. 29, 30 Recently, the crosis of the arterial wall plays a primary role in the ultimate arterial rupture. 6, 15 The absence of a mucosal inflammatory reaction at the site of the arterial rupture indicates that an acidpeptic process is not involved. 6 For colonic Dieulafoy's lesion, an additional mechanism has been suggested where by solid bowel content can contribute to mucosal stercoral ulceration over an abnormally dilated submucosal arteriole and lead to subsequent rupture and hemorrhage. 6 The stomach is the most common site for Dieulafoy's lesions. 7, 16 Of these lesions, 80% to 95% occur within 6 to 10 cm of the gastroesophageal junction, generally along the lesser curvature of the stomach. 1, 6, 14 Approximately one-third of lesions are extragastric, located most frequently in the duodenum followed by the colon. 19 They have also been described in the esophagus, jejunum, ileum, rectum, and anal canal. [20] [21] [22] [23] 
EPIDEMIOLOGY AND CLINICAL PRESENTATION
Dieulafoy' s lesion can occur at any age. The mean age of presentation is in the fifth decade of life, and there appears to be no familial predisposition associated with the lesion. 6 It is seen twice as frequently in men as in women 6 and may be more common in patients with co-morbidities such as cardiovascular diseases, chronic renal diseases, hypertension, and diabetes mellitus. 4, 14 It has also been associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and antiplatelet aggregation agents, although the effects of heavy smoking and alcohol consumption are not consistently welldocumented. 3, 6, 14, 24 The characteristic clinical presentation is sudden onset of painless, massive, recurrent, intermittent hematemesis at times associated with melena, hematochezia, and hypotension. 
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usefulness of double balloon enteroscopy (DBE) or single balloon enteroscopy (SBE) has been suggested for the detection of a Dieulafoy's lesion in the small bowel. In patients who underwent DBE or SBE because of suspected mid-GI bleeding, a Dieulafoy's lesion of the small bowel was identified as the source of bleeding in 3.5% of patients, and a mean of 1.5 enteroscopy sessions were required to establish diagnosis.
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Angiography
Angiography is useful when endoscopy fails to localize the lesion. There are no specific diagnostic criteria for identifying a Dieulafoy's lesion on angiography, but the diagnosis is suggested on demonstration of a tortuous and ectatic artery. 1, 6, 14 The findings during active bleeding include extravasation of contrast from a normal looking blood vessel (Fig. 2) .
ENDOSCOPIC TREATMENT OF A DIEULAFOY'S LESION
There is no consensus on the treatment of a Dieulafoy's lesion. Treatment options are dependent on the mode of presentation, site of the lesion and available expertise. In the years following the first description of this condition, most patients with a bleeding Dieulafoy's lesion were treated surgically. 3 In 1990, Goldenberg et al. 31 suggested that, before surgery, the endoscopic treatment of Dieulafoy's lesion should be attempted. With advances in endoscopic techniques, endoscopic therapy has gradually replaced surgery and has emerged as the first option for diagnosing and managing Dieulafoy's lesions. 10 Endoscopic treatment is safe and highly successful in terms of achieving initial hemostasis and hemostasis success rates reach 75% to 100% (Table 1) . 4, 7, [10] [11] [12] [13] 18, 21, 24, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] With the introduction of DBE and SBE into clinical practice, endoscopic therapy of a small-bowel Dieulafoy's lesion, has also become an attractive option.
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Classification of endoscopic treatment
Endoscopic hemostatic procedures can be classified into three groups: (1) regional injection: local epinephrine injection and sclerotherapy; (2) thermal: electrocoagulation, heat probe coagulation and argon plasma coagulation (APC); and (3) mechanical: banding and hemostatic clips. 1, 6, 9 Regional injection therapy Epinephrine is injected (dilution, 1:10,000) to four quadrants with 2.5 mL initially, with repeated injections until the cessation of bleeding is maintained. 35 It is widely available, relatively inexpensive, simple and comparatively safe in avoiding damage to the bowel wall. However, there are some limitations to the use of injection therapy as the definitive therapy for bleeding Dieulafoy's lesions. The use of epinephrine alone in the management of a suspected Dieulafoy's lesion is not advocated because of the possibility of rebleeding. 34, 49 Epinephrine preinjection around the lesion before other treatment modalities should only be used to reduce the potential for excessive bleeding during therapy. 25 Sclerotherapy using sclerosants (such as ethanol or polidocanol) can also be used for a bleeding Dieulafoy's lesion. A few studies have shown that successful control of a bleeding Dieulafoy's lesion could be achieved by local injection of polidocanol at four sites around the vessel and then into the vessel itself.
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Thermal coagulation
Thermal endoscopic hemostasis can be classified as either contact or noncontact. Bipolar electrocoagulation and heater probe coagulation are examples of contact thermocoagulation. The use of contact thermal methods alone has been criticized because of the possibility of inadequate coagulation of the lesion when covered by blood. 51 APC is a noncontact thermocoagulation technique that delivers high-frequency monopolar current through a conductive gas to the submucosa. 52 This method has advantages over contact thermal methods, because it is relatively easy to use and reduces the risk of perforation by limiting the depth of tissue damage. 53 One study reported that APC alone is a highly effective method for the treatment of an actively bleeding Dieulafoy's lesion.
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Mechanical therapy
Hemorrhage can also be controlled by mechanical methods such as endoscopic band ligation (EBL) or application of he- Values are presented as number (%). Epin, 1:10,000 epinephrine solution; HP, heat probe; Polidoc, polidocanol; EBL, endoscopic band ligation; APC, argon plasma coagulation.
moclips, both of which have been considered to be the first option in the management of Dieulafoy's lesions. 14, 54 Hemostatic clipping One of the most widely used endoscopic mechanical therapies is hemoclipping (Fig. 3) . It is suggested to be useful and more successful than injection therapy in achieving permanent hemostasis for bleeding Dieulafoy's lesions. 33 However, it is difficult to apply a hemoclip when the angle of approach is tangential or when the lesion is located at the difficult sites (particularly, the gastric fundus, the lesser curvature of the stomach, or the posterior wall of the duodenal bulb) or when the lesion has a fibrotic ulcer base. In addition, prior incorrectly deployed hemoclips can hinder the accurate positioning of subsequent hemoclips. 10, 55 Therefore, it is important to apply the hemoclips accurately on Dieulafoy's lesions, particularly the first one. 56 For this reason, endoscopic hemoclip application should be reserved for experienced endoscopists; nonetheless, it is a good therapy option for Dieulafoy's lesions. 11, 57 Band ligation EBL is another mechanical hemostatic option (Fig. 4) . The advantages of EBL are ease of use, accessibility to difficult sites (particularly, the esophagogastric junction and the posterior wall of the proximal body of the stomach), and low perforation risk. However, it also has limitations such as poor visual field, unfeasibility in fibrotic tissue, the time interval required to prepare the device, and the difficulty of re-intubation due to the presence of the band-ligating device itself. EBL is also associated with some complications such as delayed bleeding in the case of a residual vessel within a necrotic ulcer as well as perforation. 10, 37 Following the first use of EBL for Dieulafoy's lesion in 1994, 58 EBL has proven to be as effective as bipolar coagulation for Dieulafoy' s lesions and has been found to be a simple, successful, effective, and inexpensive procedure. 10, 32, 38, 59 Other endoscopic treatments Over-the-scope clip An over-the-scope clip (OTSC) has been developed for the closure of small mural defects. 60 A few studies have reported the use of OTSC for management of a Dieulafoy's lesion, 61, 62 and it may find potential application in routine endoscopic therapy of these lesions. EUS-guided treatment of the underlying vessel could be considered. EUS may help detection of the aberrant vessel in the submucosa, and it may also confirm ablation of a Dieulafoy's lesion after injection therapy or EBL by confirming absence of blood flow.
14 Which is the preferred procedure for bleeding dieulafoy's lesions?
Each technique has both advantages and disadvantages related to the hemostatic mechanism involved, the technical procedure itself, and varying success rates ( Table 2) . 39 
Monotherapy vs. combination therapy
Combination endoscopic therapy is superior to monotherapy and consists of injection therapy followed by thermal or mechanical therapy, with permanent hemostasis achieved in 95% of all cases (Fig. 5 ).
14 A lower rate of bleeding recurrence has been described with the use of combined endoscopic treatment compared with monotherapy. 9, 14, 63 
Mechanical therapy vs. other methods
Theoretically, mechanical hemostasis leads to less damage to the surrounding tissue than other modalities, 40 and several studies have shown that mechanical therapies including hemostatic clipping and EBL are more effective and successful in achieving hemostasis than other endoscopic methods, such as injection and thermal therapy. 10, 32, 33, 35, 39, 64 These reports suggest that mechanical therapy could be an appropriate first-line approach for the management of a Dieulafoy's lesions.
Of the available mechanical therapies, which is preferred?
One prospective, randomized trial reported equivalent hemostatic efficacy and clinical outcome of hemostatic clipping and EBL. 10 Another study showed EBL can be used as an initial hemostatic method for bleeding Dieulafoy's lesions because of a favorable clinical outcome comparable with that of hemostatic clipping, as well as a shorter procedure time.
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PROGNOSIS AND REBLEEDING
Advances in endoscopic techniques have reduced mortality from GI bleeding in general and dramatically in patients with a Dieulafoy's lesion-from 80% to 8%-and the need for surgical intervention has been reduced. 1 The risk of rebleeding from Dieulafoy' s lesions is reported to be 9% to 40%. The recur- 
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rence of bleeding is higher in endoscopic monotherapy compared with combination therapy. 9, 14 In addition, several studies have identified risk factors of rebleeding such as the use of NSAIDs or anticoagulants, 41 and the endoscopic findings of arterial (spurting) bleeding. 41, 63 It should be noted that the endoscopic methods of hemostasis are the preferred treatment in rebleeding from a Dieulafoy's lesion. 65 
OTHER MANAGEMENT OPTIONS FOR DIEULAFOY'S LESION
Endoscopic treatment is currently considered the first option for the management of Dieulafoy's lesions, whereas surgery or selective arterial embolization is advocated for cases with intractable bleeding or unsuccessful endoscopic therapy. 
Angiography and embolization
Angiography may also be used for both localization and therapy by gel-foam embolization of the bleeding vessel (Fig.  2) . This treatment is an effective option if endoscopic therapy is unsuccessful. However, there is a potential risk of ischemia to the area supplied by the relevant artery following angiographic embolization. If the bleeding lesion is supplied by multiple collateral vessels, angiographic embolization may be an unsuitable choice of treatment because of the risk of the resultant ischemia. 
Surgical treatment
Surgery is the last option for patients with uncontrolled recurrent bleeding or an unidentified bleeding site. The current surgical mainstay treatment is local excision or wide wedge resection, even though the mortality in emergency surgery for acute GI bleeding is quite high.
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CONCLUSIONS
Dieulafoy's lesion is increasingly being identified as a cause of major GI bleeding. With advances in GI endoscopy, as both a diagnostic and therapeutic modality, overall mortality has decreased. Therefore, endoscopy should be the initial therapeutic approach in a bleeding Dieulafoy's lesion. There are several endoscopic therapeutic methods available; however, the best modality for management of a bleeding Dieulafoy's lesion has not been clearly demonstrated. Nevertheless, there is some evidence supporting better therapeutic efficacy of combination and mechanical therapy over other endoscopic therapies. Currently, surgical intervention is used only after failure of therapeutic endoscopic and angiographic interventions and it should be guided by preoperative localization.
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